文献速递乳腺癌

Camizestrant 在绝经后 ER 阳性/HER2 阴性原发性乳腺癌中的药效学:SERENA-3 研究

Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study.
PubMed 文献 · J Clin Oncol · 2026-01-16

SERENA-3 是一项术前机会窗试验,132 例新诊断 ER 阳性/HER2 阴性绝经后乳腺癌患者随机接受 camizestrant 75、150 或 300 mg 每日一次 5-7 天,或 75 或 150 mg 每日一次 12-15 天。结果显示所有剂量使 ER 表达降低约 65%,12-15 天时 Ki67 降低幅度大于 5-7 天;75 mg 每日一次为 III 期剂量且耐受性良好。

要点

  • 所有 camizestrant 剂量使 ER 表达降低约 65%,与治疗时长无关。
  • 12-15 天时 Ki67 降低幅度大于 5-7 天,提示增殖抑制需更长时间。
  • 75 mg 每日一次为 III 期剂量,耐受性良好且达到最大药效。

核心结论

  • Camizestrant 75 mg 每日一次(III 期剂量)耐受性良好,5-7 天内通过拮抗和降解机制达到 ER 最大降低,12-15 天内抑制 Ki67 表达的肿瘤增殖。
  • 这些数据支持 camizestrant 75 mg 每日一次作为持续临床开发的首选剂量,并强调术前机会窗研究在指导剂量选择中的重要性。

研究设计与样本

  • SERENA-3 是一项开放标签、平行组、术前机会窗试验,随机分配 132 例新诊断 ER 阳性/HER2 阴性绝经后乳腺癌患者。
  • 患者接受 camizestrant 75、150 或 300 mg 每日一次 5-7 天,或 75 或 150 mg 每日一次 12-15 天。
  • 通过治疗前和治疗中肿瘤样本的 ER、PgR 和 Ki67 免疫组化分析评估药效,并进行转录组学和质谱探索性分析。

主要发现

  • 所有 camizestrant 剂量使 ER 表达降低约 65%,与治疗时长无关。
  • 12-15 天 camizestrant 治疗后 Ki67 表达降低幅度大于 5-7 天。
  • 质谱和 IHC 图像分析等探索性分析与 IHC H-score 一致,表明所有测试剂量对 ER 表达和活性及 Ki67 表达具有等效的最大效应。
  • 接受 camizestrant 75 mg 每日一次的患者中,90%-100% 报告无治疗中出现的不良事件(所有首选术语);报告的事件均为 1 级,除一例 2 级上呼吸道感染(认为与 camizestrant 无关)。

临床怎么用

  • Camizestrant 75 mg 每日一次被支持作为持续临床开发的首选 III 期剂量。
  • 术前机会窗研究可用于指导内分泌治疗的剂量选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: SERENA-3 is a presurgical window-of-opportunity (WOO) trial exploring the pharmacodynamic effects of camizestrant in postmenopausal women with newly diagnosed estrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative breast cancer. METHODS: This open-label, parallel-group trial randomly assigned 132 participants to receive camizestrant 75, 150, or 300 mg once daily for 5-7 days or 75 or 150 mg once daily for 12-15 days. The effects of camizestrant on ER expression, activity, and tumor proliferation were assessed in pre- and on-treatment tumor samples by immunohistochemical (IHC) analysis of ER, progesterone receptor (PgR), and Ki67. Exploratory analyses using transcriptomics and mass spectrometry were also performed. RESULTS: ER expression was reduced by approximately 65% for all camizestrant doses, regardless of treatment duration. Reduction in Ki67 expression was greater after 12-15 days of camizestrant treatment, compared with 5-7 days. Exploratory analyses including mass spectrometry and IHC image analysis aligned with IHC H-score, indicating equivalent, maximal effects of all tested doses of camizestrant on ER expression and activity and Ki67 expression. Of those participants receiving camizestrant 75 mg once daily, 90%-100% reported no treatment-emergent adverse events across all preferred terms; of those reported, all were Grade 1 except one participant with Grade 2 upper respiratory tract infection, not considered related to camizestrant. CONCLUSION: SERENA-3 demonstrates that camizestrant 75 mg once daily (Phase III dose) is well-tolerated and achieves maximal reduction in ER through known mechanisms, that is, antagonism and degradation, by 5-7 days, and proliferation suppression determined by Ki67 expression, by 12-15 days. These data support camizestrant 75 mg once daily as the preferred dose for ongoing clinical development and highlight the importance of presurgical WOO studies in guiding dose selection.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Robertson JFR, Gogitidze T, Katashvili Z, et al. Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study. J Clin Oncol. 2026. PMID: 41628308. doi:10.1200/JCO-25-01548

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。